Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05486884
Other study ID # CHM-2022/S03/07
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date July 1, 2023
Est. completion date April 1, 2027

Study information

Verified date July 2022
Source Centre Hospitalier le Mans
Contact Christelle JADEAU
Phone +33244710781
Email cjadeau@ch-lemans.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Out-of-hospital cardiac arrest is a public health problem for which overall survival is below 10%. Post-cardiac arrest syndrome is the principal cause of death in intensive care units (ICU), due to refractory shock or brain injuries secondary to anoxia. Brain anoxia is responsible for severe neurological sequelae that may be aggravated by cerebral hypoperfusion during the first few hours after the return of spontaneous circulation. Current recommendations are to ensure that arterial blood pressure is sufficient for the perfusion of organs, but no minimum threshold mean arterial pressure (MAP) has been defined. In practice, most teams target a MAP of at least 65 mmHg. Several observational studies have shown a correlation between MAP and neurological prognosis, patients with a higher initial MAP having a better outcome. Recent pilot studies have demonstrated the feasibility of increasing the target MAP after cardiac arrest, but conflicting results have been obtained concerning patient prognosis. These findings may be explained by changes to the autoregulation of the brain after cardiac arrest, with a shift of the curve towards the right, or its abolition. Cerebral blood flow is dependent on MAP, and a target MAP of 65 mmHg for these patients may result in insufficient brain perfusion. Conversely, a too high MAP might cause brain lesions due to vasogenic edema, hemorrhagic complications or excess perfusion in conditions of diminished brain metabolism. An interventional study is required to evaluate the effect of increasing MAP on neurofunctional outcome after cardiac arrest. Given the data available for brain autoregulation, the correlation between MAP and prognosis, and the risks theoretically associated with a higher MAP, investigator plans to compare a standard threshold of MAP (≥ 65 mmHg) with a high threshold of MAP (≥ 90 mmHg). Investigator hypothesizes that a high MAP within the first 24 hours after cardiac arrest will improve neurofunctional outcome.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 1608
Est. completion date April 1, 2027
Est. primary completion date January 1, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Admission to ICU following an out-of-hospital cardiac arrest with an initially shockable or non-shockable rhythm ; - Sustained ROSC defined as 20 minutes with signs of circulation without the need for chest compressions; - Under invasive mechanical ventilation for coma, defined as a Glasgow score = 8/15; - Consent from a relative or of a procedure for emergency inclusion. Exclusion Criteria: - Age < 18 years ; - No-flow duration > 10 minutes or unknown (time between CA and the start of cardiopulmonary resuscitation) ; - Low-flow duration > 45 minutes (time between the start of cardiopulmonary resuscitation and ROSC) ; - Unwitnessed CA with initial rhythm of asystole - Time between ROSC and inclusion > 6 hours ; - Cardiac arrest in a context of multiple trauma ; - Cardiac arrest in a context of hemorrhagic shock or severe hemorrhage necessitating hemostasis (surgery or radiological or endoscopic hemostasis) ; - Cardiac arrest secondary to an acute brain disease (ischemic or hemorrhagic stroke, subarachnoid hemorrhage, severe traumatic brain injury) ; - Refractory circulatory insufficiency: Defined as a MAP < 65 mmHg for more than one hour on norepinephrine or epinephrine at a dose > 1 µg/kg/min despite adequate fluid resuscitation ; - Extracorporeal circulatory support for refractory cardiogenic shock before inclusion ; - Extracorporeal respiratory support by Extra-Corporeal Membrane Oxygenation (ECMO) for severe acute respiratory distress syndrome before inclusion ; - Extracoporeal circulatory support before ROSC - Decision to limit care before inclusion ; - Modified Rankin score of 4 or 5 before cardiac arrest ; - Inclusion in another interventional study in which the principal endpoint is neurological prognosis ; - Pregnancy or breast feeding ; - Adult patient under legal protection (incapable adult or ward of court) ; - Patient already included in this trial ; - Absence of social security cover.

Study Design


Intervention

Procedure:
Maintain MAP = 90 mmHg
Maintain MAP = 90 mmHg for the 24 hours following inclusion by perfusion of norepinephrine
Maintain MAP = 65 mmHg
Maintain MAP = 65 mmHg for 24 hours after randomization through the perfusion of norepinephrine

Locations

Country Name City State
France Centre Hospitalier Du Mans Le Mans

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier le Mans

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of patients with a good neurofunctional outcome 180 days after inclusion Good neurofunctional outcome will be defined by a modified Rankin scale (mRS) of 0 to 3.This score is a global evaluation scale for disability, with seven levels (0 = no symptoms; 6 = patient dead).Ihis score will be measured by psychologist who will be blinded to the randomization arm. 180 days after inclusion
See also
  Status Clinical Trial Phase
Recruiting NCT06048068 - Removing Surrogates' Uncertainty to Reduce Fear and Anxiety After Cardiac Events N/A
Recruiting NCT05558228 - Accuracy of Doppler Ultrasound Versus Manual Palpation of Pulse in Cardiac Arrest
Completed NCT03685383 - Cytokine Adsorption in Post-cardiac Arrest Syndrome in Patients Requiring Extracorporeal Cardiopulmonary Resuscitation N/A
Completed NCT04584645 - A Digital Flu Intervention for People With Cardiovascular Conditions N/A
Completed NCT04619498 - Effectiveness of an Interactive Cognitive Support Tablet App to Improve the Management of Pediatric Cardiac Arrest N/A
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Withdrawn NCT02352350 - Lactate in Cardiac Arrest N/A
Completed NCT03024021 - Cerebral Oxymetry and Neurological Outcome in Therapeutic Hypothermia
Completed NCT02275234 - Care After Resuscitation
Completed NCT02247947 - Proteomics to Identify Prognostic Markers After CPR and to Estimate Neurological Outcome
Completed NCT01936597 - Prospective Study of 3 Phone Assistance Strategies to Achieve a Continuous Cardiac Massage N/A
Completed NCT01944605 - Intestinal Ischemia as a Stimulus for Systemic Inflammatory Response After Cardiac Arrest N/A
Completed NCT01972087 - Simulation Training to Improve 911 Dispatcher Identification of Cardiac Arrest N/A
Active, not recruiting NCT01239420 - Norwegian Cardio-Respiratory Arrest Study
Completed NCT00878644 - Therapeutic Hypothermia to Improve Survival After Cardiac Arrest in Pediatric Patients-THAPCA-OH [Out of Hospital] Trial Phase 3
Completed NCT00880087 - Therapeutic Hypothermia to Improve Survival After Cardiac Arrest in Pediatric Patients-THAPCA-IH [In Hospital] Trial N/A
Completed NCT01191736 - Ultra-Brief Versus Brief Hands Only CPR Video Training With and Without Psychomotor Skill Practice N/A
Completed NCT00729794 - Vasopressin, Epinephrine, and Steroids for Cardiac Arrest Phase 3
Recruiting NCT00441753 - Cerebral Bloodflow and Carbondioxide Reactivity During Mild Therapeutic Hypothermia in Patients After Cardiac Arrest N/A
Completed NCT00347477 - Fluid Shifts in Patients Treated With Therapeutic Hypothermia After Cardiac Arrest Phase 3